Xeloda chemo regimen superior in Phase III adjuvant colon cancer trial
This article was originally published in Scrip
Executive Summary
Roche's oral chemotherapy drug Xeloda (capecitabine) in combination with the intravenous chemotherapy oxaliplatin has delayed recurrence in adjuvant colon cancer for longer than a standard chemotherapy, 5-fluorouracil/leucovorin, in a Phase III trial.